Driving Insight into Structural and Biophysical Properties Through Analytical Programs

The delivery of antisense oligonucleotides (ASOs) to their intended intracellular sites of action remains a significant hurdle that must be overcome in order to realize broader clinical applications for this product class.

In this article, our expert, Ashleigh Wake, UK Business Development Director, discusses a variety of promising delivery technologies which are designed to promote cellular uptake including lipid-based, nano-particle based, and ligand conjugation approaches as well as providing an overview on the methodologies to assess those critical quality attributes required to support development and regulatory submissions.

Please complete the form to download our eBook: